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Abstract
Aspergillosis and candidosis remain the most prevalent opportunistic fungal infections in immunocompromised patients, but diseases
caused by the Zygomycetes have become of increasing importance. Exposure to antimycotic drugs with no activity against zygomycetes
may be a new risk factor and an explanation for the increasing incidence of zygomycosis. The latter infection occurs only rarely in
immunocompetent hosts, but in recent years Apophysomyces elegans has been described in many subtropical countries as an emerging
pathogen causing mostly cutaneous infections after traumatic inoculation.
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Introduction
Infections due to zygomycetes were ﬁrst recognized and
described by pathologists at the end of the 19th century in
Germany [1]. The detailed description suggests that the ﬁrst
case of zygomycosis in a cancer patient was caused by Absidia
corymbifera [2]. Furthermore, one of the oldest fungal iso-
lates in the Centraalbureau voor Schimmelcultures in the
Netherlands fungal collection is a Rhizopus oryzae isolate
recovered from rotting fruit collected in 1892 in Indonesia.
In the second half of the 20th century, most cases of
opportunistic fungal infections, including zygomycosis, can be
regarded as complications of medical treatment. The increase
in the incidence of cancer and the progress in intensive-care
treatment, including organ transplantations, advanced myelo-
suppressive cancer treatments, and liberal use of corticoster-
oids, have resulted in more and more immunocompromised
patients being vulnerable to invasive fungal infections. Asper-
gillosis and candidosis still remain the most prevalent oppor-
tunistic infections in such patients, but diseases caused by
zygomycetes have become of increasing importance. In addi-
tion to cancer patients, those with diabetic ketoacidosis,
solid organ or bone marrow transplants, or iron overload,
and those receiving immunosuppressive agents, are also at
high risk of developing zygomycosis. It is both interesting and
worrisome that an increase in the incidence of zygomycosis
in solid organ transplant recipients has been observed in
recent years, in parallel with the introduction of caspofungin
and voriconazole [3]. At a large centre in Austria, only three
cases of zygomycosis were encountered until December
2003, but seven cases occurred in the following period,
when voriconazole was used extensively [4]. This type of
experience has been reported from many other centres
[5,6]. Treatment or prophylaxis with voriconazole, itraconaz-
ole or caspofungin seems to be associated with the develop-
ment of zygomycosis. More intensive chemotherapy and
immunosuppression, combined with exposure to antimycotic
drugs that are not active against zygomycetes, may be new
risk factors. Patients with a dual mycotic infection, i.e. Asper-
gilllus and a zygomycete, are not uncommon. Thus, treating
patients with antifungal drugs registered for aspergillosis
might select the concomitant zygomycete, leading to a fatal
outcome, although the Aspergillus infection was eradicated. In
addition, there seem to be more reports of zygomycosis
after traumatic inoculation due to accidents or natural disas-
ters, where, especially on the Indian subcontinent, Apophy-
somyces elegans seems to have become an emerging
pathogen [7]. This review will concentrate on the latter
pathogen as an emerging infectious agent.
Epidemiology
The clinical spectrum of zygomycosis is now broader, and it
can be difﬁcult to distinguish between the well-recognized
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mucormycosis and the more rarely encountered entomoph-
thoramycosis, both of which can manifest as diseases ranging
from a superﬁcial to an angio-invasive infection with high
mortality.
The overall survival rate of patients with zygomycosis is
c. 50%, although survival rates of up to 85% have been
reported more recently. Much of the variability in favourable
outcome is due to the various forms of the disease. Rhino-
cerebral zygomycosis has a higher survival rate than does
pulmonary or disseminated zygomycosis, because the rhino-
cerebral disease can frequently be diagnosed earlier. Both
surgical intervention and treatment of the most common
underlying cause of this fungal infection, diabetic ketoacidosis,
account for this better survival rate. In contrast, pulmonary
zygomycosis has a high mortality rate (65% at 1 year),
because it is difﬁcult to diagnose, it frequently occurs in neu-
tropenic patients, and surgical intervention is rarely possible.
The largest and most comprehensive review to date on
929 cases of zygomycosis was published by Roden et al. [8].
They reported a prevalence and an overall mortality of 36%
and 44%, respectively, for diabetes; of 19% and 35%, respec-
tively, for patients with no underlying condition; and of 17%
and 66%, respectively, for patients with a malignancy. The
most common sites of infection were the sinuses (39%),
lungs (24%), and skin (19%). Dissemination was seen in 23%
of cases. Mortality varied with the site of infection: 96% of
patients with disseminated disease, 85% with gastrointestinal
infection, and 76% with pulmonary infection died.
The epidemiology of zygomycosis seems to be different
between developed and developing countries. In developed
countries, the disease is still a rare ﬁnding, and is at present
mostly seen in patients with haematological malignancies
those undergoing chemotherapy, in bone marrow transplant
recipients, and as a breakthrough infection, as stated before,
in patients receiving voriconazole therapy or prophylaxis.
However, in developing countries, especially in India, the
number of zygomycosis cases seems to be on the increase,
occurring commonly in patients with uncontrolled diabetes
[9]. The number of cases with uncontrolled diabetes is so
overwhelming that other risk factors are overshadowed.
Cases are also seen in patients with haematological malignan-
cies or in transplant recipients, but the number is minuscule
as compared with that in diabetics. In only one centre in
India, clinicians encountered 129 cases (over 10 years) [10]
in 2001, followed by 178 cases (over 5 years) in 2006, and
recently already 75 cases (over 18 months) in 2009 [10a].
All cases, mostly in diabetics, were proven cases. Therefore,
there seems to be a dichotomy of risk factors in zygomyco-
sis from two parts of the world. In the developed world, dia-
betes has become less of a risk factor in the last 25 years.
For example, in India, most diabetics are ignorant of the dis-
ease. In fact, the presence of diabetes was diagnosed in sev-
eral patients during investigation for the predisposing factor
for zygomycosis. In India, there are more than 30 million dia-
betics, and the majority are poorly compliant, putting them
at risk of developing opportunistic zygomycosis [11].
However, not all members of the Mucorales are true
opportunists. The genera Apophysomyces and Saksenaea can
initiate invasive disease in apparently normal hosts who have
sustained penetrating trauma during accidents.
Entomophthorales are endemic to regions of the world
with tropical climates, where most cases of infection are
seen. Entomophthoramycosis, a chronic and slowly progres-
sive disease, includes two clinically and mycologically distinct
entities called basidiobolomycosis and conidiobolomycosis,
seen mostly in immunocompetent patients living in India,
South America, and Africa, but also as rare emerging infec-
tions in the Western world [12–14]. As a general rule,
entomophthorales, but also Apophysomyces, occur in
immunocompetent hosts, and are locally progressive through
direct extension into neighbouring tissues, but they are
rarely angio-invasive and rarely become disseminated, as is
seen with mucorales.
Ante-mortem diagnosis has been made infrequently in
cases of pulmonary zygomycosis, because of the sudden
course of the disease, and the lack of consideration of zygo-
mycosis, despite the help from computed tomography/mag-
netic resonance imaging in localizing the site of the lesion for
the performance of ﬁne-needle aspiration under computed
tomography guidance. Cultures of respiratory material are
usually negative, but a positive culture in an appropriate host
is highly suggestive of invasive disease. However, there are
rarely clinical and microbiological clues available in gastroin-
testinal zygomycosis. Most patients with this disease are
premature babies with necrotizing enterocolitis. Few ante-
mortem cases of gastrointestinal zygomycosis are picked up
during surgery.
Proven infection always requires histopathological demon-
stration of tissue invasion with the typical irregular, broad,
non-septated hyphae. As culture of tissue can give variable
results, histologically positive parafﬁn-embedded material
with negative cultures should always be subjected to DNA-
based identiﬁcation.
Apophysomyces elegans
Before the zygomycete A. elegans, belonging to the family
Mucoraceae, was recognized as causing severe human infec-
tions, it was ﬁrst described in soil samples from a mango
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orchard in India in 1979 [15]. A few years later, this patho-
gen was found in a clinical case with a trauma injury and was
also cultured from environmental samples [16]. Infections
with Apophysomyces are mostly acquired in tropical and sub-
tropical areas, and cases have been described from several
states in the USA (Texas [17–21], Arizona [22–25], Florida
[26,27], Mississippi [28], Oklahoma [29], Georgia [30] Minne-
sota [31], Alabama [32], South Carolina [33]), different
regions in India [34–45], Venezuela [46], Colombia [47],
Mexico [20,48], Australia [16], Saudi Arabia [49], and Kuwait
[50]. A case described from The Netherlands was linked to
a subtropical source in the Caribbean [51]. Infection with
A. elegans is mainly the result of the inoculation of soil or
plant detritus during an accident. This was well appreciated
after the tsunami disaster in 2004, when victims were found
to be infected with Apophysomyces contracted in Sri Lanka
[52] and Thailand [53]. Well-described causes of traumatic
inoculation are motocycle and other road trafﬁc accidents,
but the incident can be so minor that the patient does not
remember any injury, as in the case from The Netherlands
[51]. Although inhalation of A. elegans spores can result in
rhinocerebral and pulmonary infections, local wound contam-
ination after an accident represents the single most common
host risk factor. The majority of involved patients demon-
strate no underlying immune system dysfunction. Only a few
patients with A. elegans infection had risk factors for develop-
ing zygomycosis; among others, diabetes, severe burns, renal
transplantation, myeloﬁbrosis, and corticosteroid use. The
most common site of disease manifestation of A. elegans
infection is the cutaneous and subcutaneous tissue, with local
invasion into muscle and fat tissue resulting in necrotizing
fasciitis. Thrombosis with extensive necrosis of the involved
tissues is common [16,22,29,34,46,48]. Exudates from the
lesion often include necrotic debris and thick pus reminiscent
of a Staphylococcus aureus infection [16,51].
A. elegans is a thermotolerant fungus that is capable of
rapid growth at 24–43C in vitro [15,51,54], and it is believed
that this thermotolerance permits fungal proliferation in deep
tissues. Although no speciﬁc virulence factors have yet been
identiﬁed for this organism, it produces disease in much the
same way as the other mucorales, with tissue and angio-inva-
sion. Apophysomyces infections do not have a high death rate;
this is most probably associated with its occurrence in
immunocompetent patients, the relatively easy surgical treat-
ment of cutaneous sites, and the availability of lipid prepara-
tions of amphotericin B.
The microscopic morphology seen in tissues infected with
A. elegans is similar to that seen with other zygomycetes. Pleo-
morphic, thin-walled, aseptate hyphal elements invade both
tissues and blood vessels. Hyphae may be twisted and
collapsed, demonstrating bulbous vesicles and irregular
branching. The inﬂammatory response seen with A. elegans
infection is quite variable, but most histopathological descrip-
tions show acute inﬂammation with necrosis and abscess
formation.
A. elegans grows as a ﬂoccose aerial mycelium, demonstrat-
ing white to grey conﬂuent growth in 2 days on standard cul-
ture medium. It is a thermophilic fungus, showing rapid
growth in a temperature range from 25C to 43C. A. elegans
has fastidious culture requirements for sporulation. It never
sporulates on standard media, but produces only sterile hya-
line hyphae. Nutrient-deﬁcient growth medium and prolonged
incubation induce sporulation, which is necessary for identiﬁ-
cation of the fungus with its distinct microscopic morphology
[17,22,28,51], the very prominent ﬂask or bell-shaped apoph-
ysis. A. elegans is sometimes confused with Saksenaea vasifor-
mis, owing to their fastidious culture requirements and
disease manifestations [54]. Like A. elegans, the zygomycete
S. vasiformis generally produces sterile hyphae on routine cul-
ture media. The increasing use of molecular identiﬁcation by
internal transcribed spacer (ITS) sequences in clinical mycol-
ogy will, in particular, facilitate a speciﬁc aetiological diagnosis
of this, until recently, elusive pathogen [7].
Conclusions
The emergence of unusal agents of zygomycosis is exempli-
ﬁed by Apophysomyces elegans. Undoubtedly, other species
will be described causing human infection, especially in the
presence of new antifungal treatments and underlying medi-
cal condition.
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